The bottom line, as far as I can tell: $5.6m in cash right now, $1.3m R&D tax refund due. $3m revenue, $5.9m expenditure for a $2.9m loss. So they should be OK for money in the short term. To state the bleeding obvious, if they were able to increase their earnings by a factor of 2 they'd be breaking even.
Interesting that endometriosis gets prominent position early on in the report, we already knew that looked like the next major focus of the company, I think the highlighting just reinforces that.
There's that feeling that I suspect many of you have had for a long time: this is so close to taking off, it just needs all the ducks to get lined up properly.
PIQ Price at posting:
$1.10 Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)